Back to top

oncology-screening: Archive

Shaun Pruitt

2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL

Investors looking for a momentum stock that could be in store for higher highs may want to consider Celestica (CLS), while those looking for a buy-the-dip target have an intriguing option with Exelixis (EXEL).

EXELNegative Net Change CLSPositive Net Change

Ahan Chakraborty

Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?

Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.

AZNPositive Net Change BMYPositive Net Change MRKNegative Net Change MRNANegative Net Change ABBVNegative Net Change

Ahan Chakraborty

Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?

Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.

SDGRPositive Net Change RLAYNegative Net Change RXRXNegative Net Change